AIHTA - Publications - Search - Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)

Rothschedl, E. and Grössmann, N. (2024): Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC). Fact Sheet Nr. 180.

[thumbnail of Fact Sheet Nr.180.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
319kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 400-600 Ureter. Bladder. Urethra
Language:English
Series Name:Fact Sheet Nr. 180
Deposited on:07 Aug 2024 11:23
Last Modified:10 Jul 2025 11:38

Repository Staff Only: item control page